Novartis Pharma President: Diovan Mess Hurt Japan Sales And Reputation
This article was originally published in PharmAsia News
Executive Summary
Sales at Novartis in Japan have declined as a result of data falsification allegations for Diovan (valsartan) clinical trials, according to statements made by Pharma Division President David Epstein during an Oct. 3 press conference.
Sales at Novartis in Japan have declined as a result of data falsification allegations for Diovan (valsartan) clinical trials, according to statements made by Pharma Division President David Epstein during an Oct. 3 press conference. However, Epstein said that he is more worried about the company’s reputation. Japan is a growing market and an important investment for Novartis, and trust and reliability of doctors is important. The occurrence in the Japan market has been felt worldwide, according to Epstein. Novartis Chief Commercial Officer Eric Cornut has been appointed Chairman of Novartis Japan to strengthen internal governance measures. Kornut will work with Japan CEO Ninomiya towards the improvement of compliance and corporate ethics in Japan, Epstein said. (Click Here For More – Japanese Language
)
“Novartis HQ’s President Epstein: Sales Are Down Due To Diovan Problem, But Emphasis On Effect Of Decreased Reliability” - mixonline.jp 10/04/2013